Dermata Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
DRMA$0.71-7.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| For the nine months ended September 30, | ||||
|---|---|---|---|---|
| 2026 · 2025 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $(7,636,169) | $(5,696,669) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization | 12,911 | - | ||
| Stock-based compensation | 127,237 | 114,263 | ||
| Increase (decrease) in cash resulting from changes in: | ||||
| Prepaid expenses and other current assets | (243,384) | (34,965) | ||
| Inventories | (825,279 ) | - | ||
| Other assets | (45,637) | - | ||
| Accounts payable | 1,175,127 | (304,089) | ||
| Accrued and other current liabilities | (115,829) | (506,902) | ||
| Net cash used in operating activities | (7,551,023) | (6,428,362) | ||
| Cash flows from investing activities: | ||||
| Purchases of property and equipment | (163,647) | - | ||
| Net cash used in investing activities | (163,647) | - | ||
| Cash flows from financing activities: | ||||
| Proceeds from issuance of Common Stock from ATM sales, net of issuance costs | 1,994,051 | - | ||
| Proceeds from issuance of Common Stock, pre-funded warrants, and warrants, net of issuance costs | 3,312,350 | 7,980,804 | ||
| Proceeds from exercise of pre-funded warrants | - | 977 | ||
| Payment of issuance costs | (91,352) | (50,495) | ||
| Payment for fractional shares in reverse stock split | - | (367) | ||
| Net cash provided by financing activities | 5,215,049 | 7,930,919 | ||
| Net increase (decrease) in cash and cash equivalents | (2,499,621) | 1,502,557 | ||
| Cash, cash equivalents and restricted cash at beginning of period | 7,521,978 | 3,161,570 | ||
| Cash, cash equivalents and restricted cash at end of period | $5,022,357 | $4,664,127 | ||
| Reconciliation of cash, cash equivalents and restricted cash to the balance sheets | ||||
| Cash and cash equivalents | $4,822,357 | $4,664,127 | ||
| Restricted cash | 200,000 | - | ||
| Total cash, cash equivalents and restricted cash | $5,022,357 | $4,664,127 | ||
| Non-cash investing and financing activities: | ||||
| Issuance of Common Stock upon exercise of pre-funded warrants | $54 | $ | - | |
| Purchases of property and equipment included in accounts payable | $6,250 | $ | - | |
| Issuance of abeyance shares | $ | - | $(24) | |
| Issuance costs in accounts payable and accrued expenses | $114,923 | $ | - | |
| Supplemental disclosure: | ||||
| Cash paid for taxes | $950 | $950 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.